相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A liposome-based combination strategy using doxorubicin and a PI3K inhibitor efficiently inhibits pre-metastatic initiation by acting on both tumor cells and tumor-associated macrophages
Chaohui Luo et al.
NANOSCALE (2022)
Multitarget Inhibition of Histone Deacetylase (HDAC) and Phosphatidylinositol-3-kinase (PI3K): Current and Future Prospects
Daniel A. Rodrigues et al.
CHEMMEDCHEM (2021)
Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors
Ashish Thakur et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia
Xinyu Li et al.
HAEMATOLOGICA (2019)
Developed and validated stability indicating HPLC method for the determination of epirubicin in bulk drug, marketed injection and polymeric nanoparticles
Mohammad Tariq et al.
BRAZILIAN JOURNAL OF PHARMACEUTICAL SCIENCES (2018)
Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers
Kaiming Sun et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Self assembled dual responsive micelles stabilized with protein for co-delivery of drug and siRNA in cancer therapy
M. R. Aji Alex et al.
BIOMATERIALS (2017)
PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma
Yael Babichev et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2016)
PI3K Inhibitor Combined With Chemotherapy Can Enhance the Apoptosis of Neuroblastoma Cells In Vitro and In Vivo
Xianjie Geng et al.
TECHNOLOGY IN CANCER RESEARCH & TREATMENT (2016)
Novel Polymeric Nanoparticles for Intracellular Delivery of Peptide Cargos: Antitumor Efficacy of the BCL-2 Conversion Peptide NuBCP-9
Manoj Kumar et al.
CANCER RESEARCH (2014)
The activity against Ehrlich's ascites tumors of doxorubicin contained in self assembled, cell receptor targeted nanoparticle with simultaneous oral delivery of the green tea polyphenol epigallocatechin-3-gallate
Lipika Ray et al.
BIOMATERIALS (2013)
GDC-0032, a beta isoform-sparing PI3K inhibitor: Results of a first-in-human phase la dose escalation study.
Dejan Juric et al.
CANCER RESEARCH (2013)
Crucial Differences in the Hydrolytic Degradation between Industrial Polylactide and Laboratory-Scale Poly(L-lactide)
Anders Hoglund et al.
ACS APPLIED MATERIALS & INTERFACES (2012)
Customizing the Hydrolytic Degradation Rate of Stereocomplex PLA through Different PDLA Architectures
Sofia Regnell Andersson et al.
BIOMACROMOLECULES (2012)
Poly(caprolactone)-modified Pluronic P105 micelles for reversal of paclitaxcel-resistance in SKOV-3 tumors
Yongzhong Wang et al.
BIOMATERIALS (2012)
BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study
Dejan Juric et al.
CANCER RESEARCH (2012)
Cancer Network Disruption by a Single Molecule Inhibitor Targeting Both Histone Deacetylase Activity and Phosphatidylinositol 3-Kinase Signaling
Changgeng Qian et al.
CLINICAL CANCER RESEARCH (2012)
Nanotechnology-based combinational drug delivery: an emerging approach for cancer therapy
Priyambada Parhi et al.
DRUG DISCOVERY TODAY (2012)
The functions and regulation of the PTEN tumour suppressor
Min Sup Song et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2012)
Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
PI3K Inhibition Enhances Doxorubicin-Induced Apoptosis in Sarcoma Cells
Diana Marklein et al.
PLOS ONE (2012)
Adsorption behavior of epirubicin hydrochloride on carboxylated carbon nanotubes
Zhe Chen et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2011)
The phosphatidyl inositol 3-kinase/AKT signaling pathway in breast cancer
Carlos A. Castaneda et al.
CANCER AND METASTASIS REVIEWS (2010)
Effects of pluronic and doxorubicin on drug uptake, cellular metabolism, apoptosis and tumor inhibition in animal models of MDR cancers
Elena V. Batrakova et al.
JOURNAL OF CONTROLLED RELEASE (2010)
Nuclear Phospho-Akt Increase Predicts Synergy of PI3K Inhibition and Doxorubicin in Breast and Ovarian Cancer
Jeffrey J. Wallin et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics
Bryan T. Hennessy et al.
CANCER RESEARCH (2009)
Oncogenic PI3K and its role in cancer
Y Samuels et al.
CURRENT OPINION IN ONCOLOGY (2006)
Differential responses to doxorubicin-induced phosphorylation and activation of Akt in human breast cancer cells
XQ Li et al.
BREAST CANCER RESEARCH (2005)
FTIR spectroscopic study on effects of temperature and polymer composition on the structural properties of PEO-PPO-PEO block copolymer micelles
YL Su et al.
LANGMUIR (2002)
分享论文
